NFκB Silencing Induces Chromatin Acetylation and Ablates Resistance to Cisplatin in Head and Neck Cancer

Conclusion: Our results suggest that HDAC inhibitors and NFκB targeted therapies may represent viable adjuvant chemotherapy to revert HNSCC resistant to platinum-based therapies.

Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - January 21, 2014 Category: ENT & OMF Authors: ALINE CORREA ABRAHAO, LUCIANA O. ALMEIDA, LUCIANA K. ROSSELLI-MURAI, FERNANDA S. GIUDICE, ANDREIA M. LEOPOLDINO, CRISTIANE H. SQUARIZE, ROGERIO M. CASTILHO Tags: Online Only Articles Source Type: research